GlassScriptPhysician profile
Blake L Williams
NPI 1497101018
$6,422.85
in general payments reported to CMS, 2019-2025
30 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $273 · 2021: $712 · 2022: $846 · 2023: $1,310 · 2024: $1,486 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,440 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,440.48 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,078.26 | 2019-2025 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| Alcon Vision LLC | $1,025.92 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Allergan, INC. | $496.32 | 2019-2022 | |
| Rxsight INC | $476.90 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Harrow Eye, LLC | $428.31 | 2023-2025 | Vevye, Iheezo |
| Regeneron Healthcare Solutions, INC. | $400.54 | 2019-2023 | Eylea |
| Abbvie INC. | $345.08 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $257.20 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $245.44 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $224.20 | 2022-2025 | Miebo, Vyzulta, Lotemax Sm |
| Sun Pharmaceutical Industries INC. | $172.34 | 2021-2024 | Cequa |
| Mallinckrodt Hospital Products INC. | $171.91 | 2024-2025 | Acthar |
| New World Medical,INC. | $136.32 | 2023-2024 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Apellis Pharmaceuticals, INC. | $121.46 | 2023 | Syfovre |
| Alexion Pharmaceuticals, INC. | $104.89 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $96.80 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $91.77 | 2021 | |
| Beaver-Visitec International, INC. | $79.92 | 2023-2024 | |
| Sight Sciences, INC. | $61.66 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $60.50 | 2023 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $55.42 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $52.12 | 2021-2022 | |
| Thea Pharma INC. | $44.06 | 2023-2024 | Iyuzeh |
| Iridex Corporation | $41.06 | 2020 | |
| Biotissue Holdings INC. | $39.99 | 2022-2025 | |
| Astellas Pharma US INC | $31.56 | 2024-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $24.87 | 2023 | Purified Cortrophin Gel |
| Amgen INC. | $22.06 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $19.40 | 2021 | |
| Aerie Pharmaceuticals, INC. | $16.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.